Actively Recruiting
Safety and Feasibility Study of Targeted Stereotactic Radiation for Men with Locally Recurrent Prostate Cancer After Prior Radiotherapy
Led by Royal North Shore Hospital · Updated on 2026-02-06
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the feasibility, safety, and toxicity of focal stereotactic radiation treatment SBRT for men with locally recurrent prostate cancer after previous radiation therapy. Participants must have biopsy-proven localized recurrence confirmed with PSMA-PET and MRI scans. The study is designed to test increasing radiation doses to find the safest level for this condition. Participants are divided into three groups, each receiving a different dose of SBRT 36 Gy, 38 Gy, or 40 Gy, delivered in six treatments over two to three sessions per week. Before treatment, fiducial markers are inserted into the prostate to guide radiation, and some may receive a hydrogel injection to protect the rectum. Dose escalation will stop if significant toxicity occurs. During the study, participants will undergo regular weekly or biweekly reviews to monitor toxicity and side effects. Researchers will record acute and late toxicities using standardized grading scales and follow participants for up to two years to assess treatment tolerability. Serious adverse events will be promptly reported to ensure safety throughout the trial.
CONDITIONS
Brief Title
Focal Radiotherapy for Previously Treated Prostate Cancer Patients
Research Team
C
Carolyn Kwong
H
Heidi Tsang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here